Blurbs

Agilon Health (AGL) Receives a Buy from Goldman Sachs

In a report released today, Jamie Perse from Goldman Sachs maintained a Buy rating on Agilon Health (AGLResearch Report), with a price target of $34.00. The company’s shares opened today at $18.87.

According to TipRanks, Perse is an analyst with an average return of -7.8% and a 34.78% success rate. Perse covers the Healthcare sector, focusing on stocks such as Agilon Health, Option Care Health, and Tenet Healthcare.

Agilon Health has an analyst consensus of Strong Buy, with a price target consensus of $28.67, representing a 51.93% upside. In a report released today, Wells Fargo also maintained a Buy rating on the stock with a $22.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $28.36 and a one-year low of $14.36. Currently, Agilon Health has an average volume of 2.19M.

Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AGL in relation to earlier this year. Last month, Shaker Benjamin, the Chief Markets Officer of AGL sold 50,000.00 shares for a total of $1,008,227.48.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agilon Health Inc is transforming healthcare by empowering community-based physicians with the resources and expertise they need to innovate the payment and delivery of care for seniors. The company enables physicians to create their own Medicare-centric globally capitated line of business.

Read More on AGL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More